Børge Sørvoll
Director of Finance/CFO chez ARCTICZYMES TECHNOLOGIES ASA
Fortune : 259 593 $ au 31/03/2024
Profil
Børge Sørvoll is currently the Chairman of Biotec BetaGlucans AS and the Chief Financial Officer of ArcticZymes Technologies ASA. Previously, he worked as the Managing Director & Chief Financial Officer of Troms Kraft Invest AS, the Chief Financial Officer of Front Exploration AS, and a Manager at Subsea 7 Norway AS.
He holds an MBA from the University of Wyoming.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/02/2024 | 95 428 ( 0,19% ) | 259 593 $ | 31/03/2024 |
Postes actifs de Børge Sørvoll
| Sociétés | Poste | Début |
|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Director of Finance/CFO | 01/10/2014 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Chairman | - |
Anciens postes connus de Børge Sørvoll
| Sociétés | Poste | Fin |
|---|---|---|
Front Exploration AS
 Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The private company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Director of Finance/CFO | - |
Subsea 7 Norway AS
 Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The private company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Corporate Officer/Principal | - |
| Troms Kraft Invest AS | Chief Executive Officer | - |
Formation de Børge Sørvoll
| University of Wyoming | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Entreprise privées | 4 |
|---|---|
Front Exploration AS
Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The private company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Industrial Services |
Subsea 7 Norway AS
Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The private company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Commercial Services |
| Troms Kraft Invest AS | |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
